Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19. / Underwood, Alexander P.; Sølund, Christina; Fernandez-Antunez, Carlota; Villadsen, Signe Lysemose; Winckelmann, Anni Assing; Bollerup, Signe; Mikkelsen, Lotte S.; Sørensen, Anna Louise; Feng, Shan; Fahnøe, Ulrik; Lassauniere, Ria; Fomsgaard, Anders; Ramirez, Santseharay; Weis, Nina; Bukh, Jens.
In: EBioMedicine, Vol. 71, 103519, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
AU - Underwood, Alexander P.
AU - Sølund, Christina
AU - Fernandez-Antunez, Carlota
AU - Villadsen, Signe Lysemose
AU - Winckelmann, Anni Assing
AU - Bollerup, Signe
AU - Mikkelsen, Lotte S.
AU - Sørensen, Anna Louise
AU - Feng, Shan
AU - Fahnøe, Ulrik
AU - Lassauniere, Ria
AU - Fomsgaard, Anders
AU - Ramirez, Santseharay
AU - Weis, Nina
AU - Bukh, Jens
N1 - Publisher Copyright: © 2021
PY - 2021
Y1 - 2021
N2 - Background: Given the importance of neutralising antibodies in protection against SARS-CoV-2 infection, it is critical to assess neutralisation persistence long-term following recovery. This study investigated neutralisation titres against SARS-CoV-2 up to 6 months post-symptom onset in individuals with mild COVID-19. Methods: Plasma neutralisation titres in convalescent COVID-19 individuals were determined at baseline and 6 months post-symptom onset using a cell culture infectious SARS-CoV-2 assay. Total SARS-CoV-2 spike-specific IgG and IgA binding was measured using a lectin capture ELISA and compared between timepoints and correlated to neutralising titres. Findings: All 48 convalescent COVID-19 individuals were found to have detectable SARS-CoV-2 50% inhibitory dilution neutralisation titres (ID50) at baseline and 6 months post-symptom onset with mean ID50 of 1/943 and 1/411, respectively. SARS-CoV-2 neutralisation titres peaked within 1-2 months post-symptom onset. However, 50% of individuals showed comparable ID50 at baseline and 6 months post-symptom onset. Both SARS-CoV-2 spike-specific IgG and IgA levels correlated well with neutralising titres. IgG binding was found to be sustained up to 6 months post-symptom onset, whereas IgA levels declined. Interpretation: This study demonstrates durability of SARS-CoV-2 spike-specific IgG and neutralisation responses following recovery from mild COVID-19. Thus, all subjects included in this study might potentially have protective levels of neutralising antibodies 6 months post-symptom onset. This study also demonstrates a relationship between spike-specific IgA and neutralisation decline, with implications for long-term protection against SARS-CoV-2 infection. Funding: Novo Nordisk Foundation, Independent Research Fund Denmark and Danish Agency for Science and Higher Education.
AB - Background: Given the importance of neutralising antibodies in protection against SARS-CoV-2 infection, it is critical to assess neutralisation persistence long-term following recovery. This study investigated neutralisation titres against SARS-CoV-2 up to 6 months post-symptom onset in individuals with mild COVID-19. Methods: Plasma neutralisation titres in convalescent COVID-19 individuals were determined at baseline and 6 months post-symptom onset using a cell culture infectious SARS-CoV-2 assay. Total SARS-CoV-2 spike-specific IgG and IgA binding was measured using a lectin capture ELISA and compared between timepoints and correlated to neutralising titres. Findings: All 48 convalescent COVID-19 individuals were found to have detectable SARS-CoV-2 50% inhibitory dilution neutralisation titres (ID50) at baseline and 6 months post-symptom onset with mean ID50 of 1/943 and 1/411, respectively. SARS-CoV-2 neutralisation titres peaked within 1-2 months post-symptom onset. However, 50% of individuals showed comparable ID50 at baseline and 6 months post-symptom onset. Both SARS-CoV-2 spike-specific IgG and IgA levels correlated well with neutralising titres. IgG binding was found to be sustained up to 6 months post-symptom onset, whereas IgA levels declined. Interpretation: This study demonstrates durability of SARS-CoV-2 spike-specific IgG and neutralisation responses following recovery from mild COVID-19. Thus, all subjects included in this study might potentially have protective levels of neutralising antibodies 6 months post-symptom onset. This study also demonstrates a relationship between spike-specific IgA and neutralisation decline, with implications for long-term protection against SARS-CoV-2 infection. Funding: Novo Nordisk Foundation, Independent Research Fund Denmark and Danish Agency for Science and Higher Education.
KW - COVID-19
KW - IgA
KW - IgG
KW - neutralisation
KW - neutralising antibodies
KW - SARS-CoV-2
U2 - 10.1016/j.ebiom.2021.103519
DO - 10.1016/j.ebiom.2021.103519
M3 - Journal article
C2 - 34419923
AN - SCOPUS:85113156129
VL - 71
JO - EBioMedicine
JF - EBioMedicine
SN - 2352-3964
M1 - 103519
ER -
ID: 278482350